Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infant 46 to 74 days of age (both inclusive)~* Born at full term of pregnancy (≥37 weeks) and/or with a birth weight≥2.5 kg~* Subject's parent(s) or legal representative able to comply with the study procedures~Exclusion Criteria:~* Participation in another clinical study investigating a vaccine, drug, medical device, or medical procedure~* Receipt of any vaccine in the 4 weeks preceding each study vaccination~* Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, meningococcal, pneumococcal, rotavirus infection~* Know or suspected congenital, hereditary or acquired immunodeficiency~* History of seizures or encephalopathy~* Known thrombocytopenia~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection~* Chronic illness that could interfere with trial conduct or completion~* Known or suspected hypersensitivity to any of the study vaccines' active substance or excipients or history of a life-threatening reaction to a vaccine(s) containing the same substances as the study vaccines~* Contraindication to any of the study vaccines~* Known personal or maternal history of hepatitis B or hepatitis C seropositivity~* History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b or meningococcal serogroup C infection~* Receipt of immune globulin, blood or blood-derived products, immunosuppressive drugs, systemic corticosteroid since birth~* Identified as a natural or adopted child of the investigator or employee with direct involvement in the current study.

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 76 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).